Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
Status:
Enrolling by invitation
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant
chemotherapy combined with target treatments followed by radical surgery in patients with
primary high-risk/grade retroperitoneal sarcoma.
The main questions it aims to answer are:
- Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant
therapy group, compared with the surgery-only group.
- The Overall survival time in the two groups.
- The safety and tolerance in the neoadjuvant therapy group.
Participants will be allocated into two groups once they meet the inclusion criteria.
- Surgery-only Group: Patients will directly undergo surgeries after the confirmation of
diagnosis through pre-operative biopsy.
- Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined
with target treatment for three circles before the following sarcoma resectional
surgeries.
Phase:
Phase 4
Details
Lead Sponsor:
Peking University International Hospital
Collaborators:
Beijing Friendship Hospital First Affiliated Hospital Xi'an Jiaotong University Peking University First Hospital Shanghai Cancer Hospital, China Shanghai Zhongshan Hospital The Affiliated Hospital of Qingdao University